CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-21 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −10,000 | 76,246 | ||
| 2022-01-21 | Wolchko J Scott President and CEO | Option exercise | +10,000 | $2.70 | $27K | 441,546 |
| 2022-01-21 | Wolchko J Scott President and CEO | Sale | −10,000 | $38.02 | $380K | 431,546 |
| 2022-01-21 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −10,000 | $2.70 | $27K | 89,446 |
| 2022-01-20 | Wolchko J Scott President and CEO | Option exercise | +30,000 | $2.70 | $81K | 461,546 |
| 2022-01-20 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | 86,246 | ||
| 2022-01-20 | Wolchko J Scott President and CEO | Option exercise | +30,000 | $2.73 | $82K | 461,546 |
| 2022-01-20 | Wolchko J Scott President and CEO | Sale | −30,000 | $40.21 | $1.2M | 431,546 |
| 2022-01-20 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | $2.73 | $82K | 20,000 |
| 2022-01-11 | Wolchko J Scott President and CEO | Sale | −10,047 | $48.50 | $487K | 436,065 |
| 2022-01-11 | Wolchko J Scott President and CEO | Sale | −4,519 | $49.07 | $222K | 431,546 |
| 2022-01-11 | TAHL CINDY General Counsel and Secretary | Sale | −4,883 | $48.46 | $237K | 156,385 |
| 2022-01-11 | TAHL CINDY General Counsel and Secretary | Sale | −536 | $49.15 | $26K | 155,849 |
| 2022-01-11 | Valamehr Bahram Chief R&D Officer | Sale | −4,152 | $48.44 | $201K | 146,950 |
| 2022-01-11 | Valamehr Bahram Chief R&D Officer | Sale | −418 | $49.12 | $21K | 146,532 |
| 2022-01-11 | Dulac Edward J III Chief Financial Officer | Sale | −1,380 | $48.25 | $67K | 109,024 |
| 2022-01-11 | Dulac Edward J III Chief Financial Officer | Sale | −390 | $49.16 | $19K | 108,634 |
| 2022-01-11 | Chu Yu-Waye Senior VP Clinical Development | Sale | −3,547 | $48.44 | $172K | 122,211 |
| 2022-01-11 | Chu Yu-Waye Senior VP Clinical Development | Sale | −418 | $49.10 | $21K | 121,793 |
| 2022-01-10 | Wolchko J Scott President and CEO | Sale | −13,161 | $46.36 | $610K | 467,107 |
Page 13 of 26 · 503 trades